News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BTG plc (LS:BGC) Takes Exclusive License To New Class Of Cancer Drug From Cancer Research Technology And The Institute of Cancer Research


10/19/2005 5:11:25 PM

BTG (LSE: BGC), the intellectual property and technology commercialization company, today announced that it has concluded a license and research collaboration agreement with Cancer Research Technology Limited (CRT), the technology transfer company of the charity Cancer Research UK, and The Institute of Cancer Research, for a new class of cancer drug.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES